Find out all about your favorite commercial!

Advertisers

Advertisers of the Trumenba TV Spot, 'Meningitis B'

Trumenba TV commercial - Meningitis B
Trumenba

Trumenba is a groundbreaking biopharmaceutical company at the forefront of vaccine development. Established in 2014, the company is dedicated to combating devastating diseases with innovative approach...

What the Trumenba TV commercial - Meningitis B is about.

Trumenba TV commercial - Meningitis B

Title: Trumenba TV Spot - 'Meningitis B'

Introduction:The Trumenba TV spot titled 'Meningitis B' is a powerful advertisement that aims to raise awareness about the importance of protecting adolescents and young adults against the potentially deadly disease, Meningitis B. Through a compelling narrative and emotional storytelling, the commercial seeks to educate and inform viewers about Trumenba, the FDA-approved vaccine designed to prevent Meningitis B.

TV Spot Summary:The TV spot opens with a montage of scenes depicting adolescents and young adults engaging in various activities - playing sports, attending college classes, enjoying time with friends - illustrating the vibrant and active lives they lead. However, beneath the surface, a lurking danger threatens their well-being.

As the scenes transition, the ad focuses on a young woman named Sarah, who becomes the emotional centerpiece of the narrative. The viewers are introduced to her life, filled with laughter, dreams, and aspirations. Sarah is depicted as a charismatic and driven young adult who is well-loved by her peers and family.

The mood of the spot quickly shifts when Sarah is suddenly seen lying in a hospital bed, weakened and vulnerable. A somber voiceover explains that Sarah has contracted Meningitis B, a severe bacterial infection that can strike quickly and without warning, leading to life-altering consequences or even death. The camera pans to her concerned loved ones, their emotions etched across their faces as they witness her struggle.

The focus then shifts to the heart-wrenching aftermath that Sarah's condition has caused. The viewers witness the profound impact on her life as she grapples with the physical and emotional toll of the illness. The voiceover stresses that Meningitis B can be prevented through vaccination, urging viewers to take action.

The scene transitions to show Sarah again, now smiling confidently and surrounded by her family and friends. The voiceover explains that Sarah chose to fight back by getting vaccinated with Trumenba, the breakthrough vaccine developed to protect against Meningitis B.

The final moments of the TV spot emphasize the importance of Trumenba as a preventive measure. The voiceover encourages viewers to consult their healthcare providers and consider vaccination to ensure the safety and well-being of themselves and their loved ones. Contact information and resources for more information are provided on screen before the commercial concludes.

Conclusion:The Trumenba TV spot, 'Meningitis B,' delivers a poignant message about the potentially devastating effects of Meningitis B on young individuals. By showcasing a relatable character who experiences the realities of the disease, the advertisement effectively compels viewers to consider the importance of vaccination and take proactive measures to protect themselves and their loved ones. Through its emotional storytelling and compelling visuals, the TV spot serves as a powerful tool in raising awareness about Meningitis B and the potential life-saving benefits of Trumenba.

Trumenba TV commercial - Meningitis B produced for Trumenba was first shown on television on August 7, 2016.

Frequently Asked Questions about trumenba tv spot, 'meningitis b'

Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B.

Trumenba prevents invasive meningococcal disease caused by Neisseria meningitidis serogroup B. Serogroup B disease is serious and accounts for approximately one-third of invasive meningococcal disease in the United States.

Meningococcal Vaccination Serogroup B meningococcal or MenB vaccines (Bexsero®and Trumenba®)

Trumenba:® Administer 2 or 3 doses. Administer 2 doses to healthy adolescents who are not at increased risk for serogroup B meningococcal disease. Administer the second dose 6 months after the first dose. Administer 3 doses to adolescents who are at increased risk for meningococcal disease.

The meningococcal B vaccine (MenB) protects against a fifth type of meningococcal bacterium (called type B). It is fairly new and not yet recommended as a routine vaccination for healthy people. But some kids and teens who are at increased risk for meningococcal disease should get it starting from age 10.

Messina's advice to parents: “For the most complete protection I would recommend giving teens both meningitis vaccines even though the meningitis B is optional on the CDC schedule. This vaccine is so important because this disease is so fatal, and there is almost no time to intervene once your child becomes ill.”

A serogroup B meningococcal (Men B) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for Men B vaccination is 16 through 18 years of age.

Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age.

As these four primary strains are representative, they predict the ability of antibodies elicited by TRUMENBA to be active against diverse circulating strains. The hSBA responses to the 10 additional MnB test strains were 61.1%-100.0% and 75.1%-98.6% one month after dose 2 and 3, respectively.

What is the schedule for MenB? Trumenba (MenB-Fhbp, Pfizer) is either a 2-dose series with doses administered at least 6 months apart or a 3-dose series with the second and third doses administered 1–2 and 6 months after the first dose. Bexsero (MenB-4C, GSK) is a 2-dose series with doses given at least 1 month apart.

Administer 2 doses to healthy adolescents who are not at increased risk for serogroup B meningococcal disease. Administer the second dose 6 months after the first dose. Administer 3 doses to people 10 years of age or older who are at increased risk for meningococcal disease.

What is the schedule for MenB? Trumenba (MenB-Fhbp, Pfizer) is either a 2-dose series with doses administered at least 6 months apart or a 3-dose series with the second and third doses administered 1–2 and 6 months after the first dose. Bexsero (MenB-4C, GSK) is a 2-dose series with doses given at least 1 month apart.

Videos

Watch Trumenba TV Commercial, 'Meningitis B'

We analyzed TV commercials placed on popular platforms and found the most relevant videos for you:

Actors

Actors who starred in Trumenba TV Spot, 'Meningitis B'

Corey Carthew photo
Jim O'Hare photo
TV commercials

Similar commercials

Mucinex Fast-Max TV Spot, 'Cleaning House'
Samsung Pay TV Spot, 'Coffee'
707 November 12, 2015
AstraZeneca TV Spot, 'Locked'
1079 August 18, 2015
Vicks NyQuil Severe TV Spot, 'Días de reposo'
Konami TV Spot, 'Metal Gear Solid V: The Phantom Pain'
HUMIRA TV Spot, 'Food Stand'
632 August 7, 2012
Konami TV Spot, 'Yu-Gi-Oh! Duel Links'
Konami TV Spot, 'Pro Evolution Soccer 2013'
Alka-Seltzer Plus Day Cold & Flu TV Spot, 'When You Can't Work From Home'
Owens Corning TV Spot, 'Total Protection Roofing System'
Orkin Pest Control TV Spot, 'In-Outdoors'
Golden Corral Prime Rib and Shrimp Weekend TV Commercial